Mankind Pharma
Tracked across 3 events · 19 articles · First seen Mar 20, 2025 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Mankind Pharma is the licensee and will commercialize the insulin analogues in India, strengthening its diabetes portfolio and injectable segment. The deal is expected to enhance its market position and revenue potential.
Aug 20, 2026 · 6 articles
Regulatory
Impact: Arjun Juneja, COO of Mankind Pharma, highlighted India's strong pharmaceutical base and the need for collaboration.
Apr 12, 2026 · 6 articles
Business
Impact: Mankind Pharma is an existing investor; its stake may be affected by valuation changes.
Jul 30, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Mankind Pharma live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard